Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2010

Open Access 01-12-2010 | Review

Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations

Authors: Thomas Glaab, Claus Vogelmeier, Roland Buhl

Published in: Respiratory Research | Issue 1/2010

Login to get access

Abstract

Current methods for assessing clinical outcomes in COPD mainly rely on physiological tests combined with the use of questionnaires. The present review considers commonly used outcome measures such as lung function, health status, exercise capacity and physical activity, dyspnoea, exacerbations, the multi-dimensional BODE score, and mortality. Based on current published data, we provide a concise overview of the principles, strengths and weaknesses, and discuss open questions related to each methodology. Reviewed is the current set of markers for measuring clinically relevant outcomes with particular emphasis on their limitations and opportunities that should be recognized when assessing and interpreting their use in clinical trials of COPD.
Literature
1.
Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532–555.CrossRefPubMed
2.
Jones PW, Agusti AG: Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006, 27:822–832.CrossRefPubMed
3.
4.
Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PMA, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Mölken MP, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF, American Thoracic Society/European Respiratory Society Task Force on outcomes of COPD: Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008, 31:416–469.CrossRefPubMed
5.
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J: ATS/ERS Task Force: Standardisation of spirometry. Eur Respir J 2005, 26:319–338.CrossRefPubMed
6.
Sin DD, Wu L, Man SF: The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005, 127:1952–1959.CrossRefPubMed
7.
Ferrie JE, Singh-Manoux A, Kivimäki M, Mindell J, Breeze E, Smith GD, Shipley MJ: Cardiorespiratory risk factors as predictors of 40-year mortality in women and men. Heart 2009, 95:1250–1257.CrossRefPubMedPubMedCentral
8.
Young RP, Hopkins R, Eaton TE: Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur Respir J 2007, 30:616–622.CrossRefPubMed
9.
Roche N, Dalmay F, Perez T, Kuntz C, Vergnenègre A, Neukirch F, Giordanella J-P, Huchon G: Impact of chronic airflow obstruction in a working population. Eur Respir J 2008, 31:1227–1233.CrossRefPubMed
10.
Akamatsu K, Yamagata T, Kida Y, Tanaka H, Ueda H, Ichinose M: Poor sensitivity of symptoms in early detection of COPD. COPD 2008, 5:269–273.CrossRefPubMed
11.
Wise RA: The value of forced expiratory volume in 1 second decline in the assessment of chronic obstructive pulmonary disease progression. Am J Med 2006, 119:4–11.CrossRefPubMed
12.
Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CPM, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J: Interpretative strategies for lung function tests. Eur Respir J 2005, 26:948–968.CrossRefPubMed
13.
O'Donnell DE: Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006, 3:180–184.CrossRefPubMed
14.
Rabe KF: Roflumilast for chronic obstructive pulmonary disease - author's reply. Lancet 2005, 366:1846–1847.CrossRef
15.
O'Donnell DE, Laveneziana P: Physiology and consequences of lung hyperinflation in COPD. Eur Respir Rev 2006, 15:61–67.CrossRef
16.
Hankinson JL, Stocks J, Peslin R: Reproducibility of lung volume measurements. Eur Respir J 1998, 11:787–790.PubMed
17.
O'Donnell DE: Is sustained pharmacologic lung volume reduction now possible in COPD? Chest 2006, 129:501–503.CrossRefPubMed
18.
Criner GJ, Belt P, Sternberg AL, Mosenifar Z, Make BJ, Utz JP, Sciurba F: National Emphysema Treatment Trial Research Group. Effects of lung volume reduction surgery on gas exchange and breathing pattern during maximum exercise. Chest 2009, 135:1268–79.CrossRefPubMedPubMedCentral
19.
Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR: Inspiratory-to-total lung capacity predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 171:591–597.CrossRefPubMed
20.
Palange P, Ward SA, Carlsen K-H, Casaburi R, Gallagher CG, Gosselink R, O'Donnell DE, Puente-Maestu L, Schols AM, Singh S, Whipp BJ: Recommendations on the use of exercise testing in clinical practice. Eur Respir J 2007, 29:185–209.CrossRefPubMed
21.
22.
Singh SJ, Morgan MDL, Scott S, Walters D, Hardman AE: Development of a shuttle walk test of disability in patients with chronic airways obstruction. Thorax 1992, 47:1019–1024.CrossRefPubMedPubMedCentral
23.
Revill SM, Morgan MDL, Singh SJ, Williams J, Hardman AE: The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease. Thorax 1999, 54:213–222.CrossRefPubMedPubMedCentral
24.
Whipp BJ, Davis JA, Torres F, Wasserman K: A test to determine the parameters of aerobic function during exercise. J Appl Physiol 1981, 50:217–221.PubMed
25.
Porszasz J, Casaburi R, Somfay A, Woodhouse LJ, Whipp BJ: A treadmill ramp protocol using simultaneous changes in speed and grade. Med Sci Sports Exerc 2003, 35:1596–1603.CrossRefPubMed
26.
Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R: Quantifying physical activity in daily life with questionnaires and motion sensors in COPD. Eur Respir J 2006, 27:1040–1055.CrossRefPubMed
27.
Wise RA, Brown CD: Minimal clinically important difference in the six-minute walk test and the incremental shuttle walk test. COPD 2005, 2:125–129.CrossRefPubMed
28.
ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111–117.CrossRef
29.
Brown CD, Wise RA: Field tests of exercise in COPD: The six-minute walk test and the shuttle walk test. COPD 2007, 4:217–223.CrossRefPubMed
30.
Cote CG, Casanova C, Marín JM, Lopez MV, Pinto-Plata V, De Oca MM, Dordelly LJ, Nekach H, Celli BR: Validation and comparison of reference equations for the 6-min walk distance test. Eur Respir J 2008, 31:571–578.CrossRefPubMed
31.
Watz H, Waschki B, Meyer T, Magnussen H: Physical activity in patients with COPD. Eur Respir J 2009, 33:262–272.CrossRefPubMed
32.
Singh SJ, Jones PW, Evans R, Morgan MDL: Minimum clinically important improvement for the incremental shuttle walking test. Thorax 2008, 63:775–777.CrossRefPubMed
33.
Solway S, Brooks D, Lacasse Y, Thomas S: A qualitative systemic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest 2001, 119:256–270.CrossRefPubMed
34.
Murray JA, Waterman LA, Ward J, Baird JC, Mahler DA: Perceptual and physiologic responses during treadmill and cycle exercise in patients with COPD. Chest 2009, 135:384–390.CrossRefPubMed
35.
American Thoracic Society: ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003, 167:211–277.CrossRef
36.
Fensli R, Pedersen PE, Gundersen T, Hejlesen O: Sensor acceptance model - measuring patient acceptance of wearable sensors. Methods Inf Med 2008, 47:89–95.PubMed
37.
38.
Troosters T: Physical activity monitoring: a new outcome facing many challenges, but yielding promising results. COPD 2009, 6:82–83.CrossRefPubMed
39.
40.
Mahler DA, Weinberg DH, Wells CK, Feinstein AR: The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984, 85:751–758.CrossRefPubMed
41.
Mahler DA, Witek TJ: The MCID of the transition dyspnea index is a total score of one unit. COPD 2005, 2:99–103.CrossRefPubMed
42.
Witek TJ, Mahler DA: Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003, 21:267–272.CrossRefPubMed
43.
de Torres JP, Pinto-Plata V, Ingenito E, Bagley P, Gray A, Berger R, Celli B: Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD. Chest 2002, 121:1092–1098.CrossRefPubMed
44.
Watson L, Vestbo J, Postma DS, Decramer M, Rennard S, Kiri VA, Vermeire PA, Soriano JB: Gender differences in the management and experience of Chronic Obstructive Pulmonary Disease. Respir Med 2004, 98:1207–1213.CrossRefPubMed
45.
van Wetering CR, van Nooten FE, Mol SJM, Hoogendoorn M, Rutten-van Mölken MPMH, Schols AM: Systemic impairment in relation to disease burden in patients with moderate COPD eligible for a lifestyle program. Findings from the INTERCOM trial. Int J Chron Obstruct Pulmon Dis 2008, 3:443–451.PubMedPubMedCentral
46.
Bourbeau J, Ford G, Zackon H, Pinsky N, Lee J, Ruberto G: Impact on patients' health status following early identification of a COPD exacerbation. Eur Respir J 2007, 30:907–913.CrossRefPubMed
47.
Rennard S, Decramer M, Calverley PM, Pride NB, Soriano JB, Vermeire PA, Vestbo J: Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002, 20:799–805.CrossRefPubMed
48.
Mahler DA: Measurement of dyspnea: clinical ratings. In In Dyspnea: Mechanisms, Measurement and Management. Volume 2005. 2nd edition. Edited by: Mahler DA. New York: Taylor and Francis; 147–164.
49.
Haughney J, Gruffydd-Jones K: Patient-centred outcomes in primary care management of COPD - what do recent clinical trial data tell us? Prim Care Resp J 2004, 13:185–197.
50.
Borg G: Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982, 14:377–381.PubMed
51.
Borg G: Psychophysical scaling with applications in physical work and the perception of exertion. Scand J Work Environ Health 1990,16(Suppl 1):55–58.CrossRefPubMed
52.
Mador MJ, Rodis A, Magalang UJ: Reproducibility of Borg scale measurements of dyspnea during exercise in patients with COPD. Chest 1995, 107:1590–1597.CrossRefPubMed
53.
54.
Jones PW, Quirk FH, Baveystock CM, Littlejohns P: A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145:1321–1327.CrossRefPubMed
55.
Meguro M, Barley EA, Spencer S, Jones PW: Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire. Chest 2007, 132:456–463.CrossRefPubMed
56.
Jones PW: Interpreting thresholds for a clinically significant changes in health status in asthma and COPD. Eur Respir J 2002, 19:398–404.CrossRefPubMed
57.
Mühlig S, Petermann F: Illness specific data collection on quality of life of patients with asthma and chronic obstructive bronchitis. Rehabilitation 1998, 37:25–38.
58.
Ferrer M, Villasante C, Alonso J, Sobradillo V, Gabriel R, Vilagut G, Masa JF, Viejo JL, Jiménez-Ruiz CA, Miravitlles M: Interpretation of quality of life scores from the St George's Respiratory Questionnaire. Eur Respir J 2002, 19:405–413.CrossRefPubMed
59.
Schünemann HJ, Griffith L, Jaeschke R, Goldstein R, Stubbing D, Guyatt GH: Evaluation of the minimal important difference for the feeling thermometer and the St. George's Respiratory Questionnaire in patients with chronic airflow obstruction. J Clin Epidemiol 2003, 56:1170–1176.CrossRefPubMed
60.
Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW: A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987, 42:773–778.CrossRefPubMedPubMedCentral
61.
Puhan MA, Guyatt GH, Goldstein R, Mador J, McKim D, Stahl E, Griffith L, Schünemann HJ: Relative responsiveness of the Chronic Respiratory Questionnaire, St. Georges Respiratory Questionnaire and four other health-related quality of life instruments for patients with chronic lung disease. Respir Med 2007, 101:308–316.CrossRefPubMed
62.
Schünemann HJ, Puhan M, Goldstein R, Jaeschke R, Guyatt GH: Measurement properties and interpretability of the Chronic respiratory disease questionnaire (CRQ). COPD 2005, 2:81–89.CrossRefPubMed
63.
Ware JE Jr, Gandek B: Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998, 51:903–912.CrossRefPubMed
64.
Wedzicha JA, Seemungal TA: COPD exacerbations: defining their cause and prevention. Lancet 2007, 370:786–796.CrossRefPubMed
65.
Anzueto A, Sethi S, Martinez FJ: Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007, 4:554–564.CrossRefPubMed
66.
Pauwels R, Calverley P, Buist AS, Rennard S, Fukuchi Y, Stahl E, Löfdahl CG: COPD exacerbations: the importance of a standard definition. Respir Med 2004, 98:99–107.CrossRefPubMed
67.
Kessler R, Ståhl E, Vogelmeier C, Haughney J, Trudeau E, Löfdahl CG, Partridge MR: Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest 2006, 130:133–142.CrossRefPubMed
68.
Burge S, Wedzicha JA: COPD exacerbations: definitions and classifications. Eur Respir 2003, 21:46s-53s.CrossRef
69.
Jones P, Higenbottam T: Quantifying of severity of exacerbations in chronic obstructive pulmonary disease: adaptations to the definition to allow quantification. Proc Am Thorac Soc 2007, 4:597–601.CrossRefPubMed
70.
Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ: The Body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:1005–1012.CrossRefPubMed
71.
Soler-Cataluña JJ, Martínez-García MÁ, Sánchez LS, Tordera MP, Sánchez PR: Severe exacerbations and BODE index: Two independent risk factors for death in male COPD patients. Respir Med 2009, 103:692–699.CrossRefPubMed
72.
Celli BR, Calverley PMA, Rennard SI, Wouters EFM, Agusti A, Anthonisen N, MacNee W, Jones P, Pride N, Rodriguez-Roisin R, Rossi A, Wanner A: Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. Respir Med 2005, 99:1546–1554.CrossRefPubMed
73.
Puhan MA, Garcia-Aymerich J, Frey M, ter Riet G, Antó JM, Agustí AG, Gómez FP, Rodríguez-Roisín R, Moons KGM, Kessels AG, Held U: Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009, 374:704–711.CrossRefPubMed
74.
Lederer DJ, Thomashow BM, Ginsburg ME, Austin JH, Bartels MN, Yip CK, Jellen PA, Brogan FL, Kawut SM, Maxfield RA, DiMango AM, Simonelli PF, Gorenstein LA, Pearson GD, Sonett JR: Lung-volume reduction surgery for pulmonary emphysema: Improvement in body mass index, airflow obstruction, dyspnea, and exercise capacity index after 1 year. J Thorac Cardiovasc Surg 2007, 133:1434–1438.CrossRefPubMed
75.
Pompeo E, Mineo TC: Two-year improvement in multidimensional body mass index, airflow obstruction, dyspnea, and exercise capacity index after nonresectional lung volume reduction surgery in awake patients. Ann Thorac Surg 2007, 84:1862–1869.CrossRefPubMed
76.
Martinez FJ, Han MK, Andrei AC, Wise R, Murray S, Curtis JL, Sternberg A, Criner G, Gay SE, Reilly J, Make B, Ries AL, Sciurba F, Weinmann G, Mosenifar Z, DeCamp M, Fishman AP, Celli BR: National Emphysema Treatment Trial Research Group. Longitudinal change in the BODE index predicts mortality in severe emphysema. Am J Respir Crit Care Med 2008, 78:491–499.CrossRef
77.
Cote CG, Celli BR: Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J 2005, 26:630–636.CrossRefPubMed
78.
Foglio K, Bianchi L, Bruletti G, Porta R, Vitacca M, Balbi B, Ambrosino N: Seven-year time course of lung function, symptoms, health-related quality of life and exercise toleranc in COPD patients undergoing pulmonary rehabilitation programs. Respir Med 2007, 101:1961–1970.CrossRefPubMed
79.
Nasis IG, Vogiatzis I, Stratakos G, Athanasopoulos D, Koutsoukou A, Daskalakis A, Spetsioti S, Evangelodimou A, Roussos C, Zakynthoinos S: Effects of interval-load versus constant-load training on the BODE index in COPD patients. Respir Med 2009, 103:1392–1398.CrossRefPubMed
80.
Marin JM, Carrizo SJ, Casanova C, Martinez-Camblor P, Soriano JB, Agusti AG, Celli BR: Prediction of risk of COPD exacerbations by the BODE index. Respir Med 2009, 103:373–378.CrossRefPubMed
81.
Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC: Lung function and mortality in the United States: data from the First National Health and Nutriation Examination Survey follow up study. Thorax 2003, 58:388–393.CrossRefPubMedPubMedCentral
82.
Ekberg-Aronsson M, Pehrsson K, Nilsson JÅ, Nilsson PM, Löfdahl CG: Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res 2005, 6:98.CrossRefPubMedPubMedCentral
83.
Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M: A 4-year trial for Tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543–1554.CrossRefPubMed
84.
Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775–789.CrossRefPubMed
85.
Sin D, Tu J: Inhaled corticosteroids and the risk of mortality and re-admission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care med 2001, 164:580–584.CrossRefPubMed
86.
Suissa S: Effectiveness of inhaled corticosteroids in COPD, immortal time bias in observational studies. Am J Respir Crit Care Med 2003, 168:49–53.CrossRefPubMed
87.
Suissa S, Barnes PJ: Inhaled corticosteroids in COPD: the case against. Eur Respir J 2009, 34:13–16.CrossRefPubMed
88.
Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE: The effects of smoking cessation intervention on 14.5-year mortality. Ann Int Med 2005, 142:233–239.CrossRefPubMed
89.
Sin DD, Wu L, Anderson JA, Anthonisen NR, Buist AS, Burge PS, Calverley PM, Connett J.E, Lindmark B, Pauwels R.A, Postma D.S, Soriano J.B, Szafranski W, Vestbo J: Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005, 60:992–997.CrossRefPubMedPubMedCentral
90.
Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA: Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999, 340:1941–1947.CrossRefPubMed
91.
Sin DD, Anthonisen NR, Soriano JB, Agusti AG: Mortality in COPD: role of co-morbidities. Eur Respir J 2006, 28:1245–1257.CrossRefPubMed
92.
Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N: Development and first validation of the COPD Assessment Test. Eur Respir J 2009, 34:648–654.CrossRefPubMed
Metadata
Title
Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations
Authors
Thomas Glaab
Claus Vogelmeier
Roland Buhl
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2010
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-11-79

Other articles of this Issue 1/2010

Respiratory Research 1/2010 Go to the issue

Research

Anxiety is associated with diminished exercise performance and quality of life in severe emphysema: a cross-sectional study

Research

Expression, regulation and clinical significance of soluble and membrane CD14 receptors in pediatric inflammatory lung diseases

Research

Collagen V-induced nasal tolerance downregulates pulmonary collagen mRNA gene and TGF-beta expression in experimental systemic sclerosis

Research

Abdominal muscle fatigue following exercise in chronic obstructive pulmonary disease

Research

Respiratory allergy to Blomia tropicalis: Immune response in four syngeneic mouse strains and assessment of a low allergen-dose, short-term experimental model

Review

The role of the bronchial microvasculature in the airway remodelling in asthma and COPD

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits